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INTRODUCTION
Hepatic fibrosis (HF) is a scarring process in which the liver forms scar tissue due to an abnormal deposition of extracellular matrix (ECM) [1] . Recently, more and more attention has been paid to the molecular mechanisms of hepatic fibrosis. At the cellular level, it is reported that the activation of hepatic stellate cells (HSCs) in the subendothelial space may result in hepatic fibrosis [2] . Moreover, reversal or apoptosis of activated HSCs has been proven to be beneficial for the treatment or regression of hepatic fibrosis [3] . Metabolomics methods can be used to characterize the metabolic profiles of a biological system. As metabolites with relatively low molecular weight are downstream products of biological processes, their identity and concentrations in a living biological system can provide biochemical signatures for globally track ing the physiological effects and exploring the drug effects [46] . A previous study [7] systematically analyzed the protective effects of traditional Chinese medicine Hongshan Capsules, and identified the potential target biomarkers through the metabonomic approach of ultra performance liquid chromatography coupled to mass spectrometry. Therefore, metabolomics methods can be used to identify biomarkers for clinical drug therapy, especially in cancer research [8, 9] . Taurine, a betaamino acid with a simple structure that is extracted from animal tissue, has been in vestigated as a promising drug for the treatment of many hepatic injuries [1013] . In previous studies, taurine was showed to significantly increase the apoptosis of HSCs and raise the levels of 19 proteins related to cellular apoptosis or oxidation in HSCs [14, 15] . However, the exact metabolic pathways and molecules involved in the mechanisms of action of taurine are still un known. Therefore, this study aimed at developing a reliable and simple method to find important biological metabolites and pathways that are related to taurine in HSCs, in order to provide more data for taurine therapy.
MATERIALS AND METHODS

Cell culture and cell viability assay
Human HSCs (LX2) were obtained from Xiangya Central Experiment Laboratory of Central South University (Changsha, China) and were incubated in DMEM (Thermo Scientific Hyclone, Logan, UT, United States) containing 100 U/mL penicillin (North China Pharmaceutical, China), 100 μg/mL streptomycin (North China Pharmaceutical, China) and 10% fetal bovine serum (Biochrom AG, Berlin, Germany) at room temperature in an incubator with 50 mL/L CO2 and saturated humidity. The culture medium was replaced every two days. Trypsin (0.25%) was added for digestion when the confluence of HSCs reached 80%90% and the supernatant was discarded after centrifugation at 1000 r/min for 5 min. Then, the cells were resuspended to a density of 5 × 10 5 /mL. MTT method was used to determine the optimum drug concentration of taurine for the subsequent study. Briefly, HSCs were added into a 96well plate at a density of 5 × 10 4 cells per well. Natural taurine (Yuanlong Pearl Co. Ltd., Beihai, China) was dissolved in dimethyl sulphoxide (DMSO) at a concentration of 8 mol/L, and then diluted with 2% DMEM to 10, 20, 40, 60, 80 and 100 mmol/L. Six replicates were applied for each concentration of taurine and the whole reaction system was maintained for 48 h. Cells treated with DMSO alone were used as controls. Subsequently, 10 μL of MTT solution (5 mg/mL in PBS) was added and the cells were further incubated for 4 h at 37 ℃. Then, the reaction was terminated by the addition of 100 μL DMSO and absorbance was measured at 495 nm using a microplate reader (Molecular Devices, United States). Based on the results, the concentration of 40 mmol/L was chosen as the optimum drug concentration of taurine for the following study.
Sample preparation
For the following metabolomic study, HSCs were incubated in 10cm culture dishes until approximately 70% confluence and then treated with celastrol and other control drugs for 12 h. Each dish was washed twice at 37 ℃ with PBS after removing the culture medium, and dried in the vacuum. Then, the cells were quenched by adding 1.5 mL HPLCgrade methanol at 80 ℃ and were separated from the culture dish with a cell lifter (Fisher Scientific, United States). The cell solution was subsequently transferred to a 2 mL centrifuge tube and frozen in liquid nitrogen until liquid liquid extraction. Six replicates were applied for 40 μmol/L of natural taurine for 48 h as the test group and the same concentration of DMSO was used as the control group. To avoid cell cytotoxicity, the final concentration of DMSO must be less than 0.1% for both the taurine group and the control group. Additionally, five parallel blank culture dishes were trypsinized and counted for the normalizing the subsequent analysis. After incubation, the culture medium was removed generally and the residual medium was removed by using 2 mL 0.9% [w/v] icecold isotonic saline (NaCl) to arrest cellular metabolism. Subsequently, the cells were added with 1 mL cold methanol/water (4:1) to quench cells and then collected in 2 mL centrifuge tubes. Then, the cells were ultrasonicated for 5 min (5 s ultrasonication at a 10s interval) in an ice bath and centrifuged at 13000 g for 10 min at 4 ℃. Finally, the supernatant was dried with nitrogen and stored at 80 ℃ before detection. 
Chromatography and spectrometry conditions
Data processing and statistical analysis
After excluding the noise and background interference, raw mass spectral data of both ESI + and ESI modes were analyzed by using Mass Profiler (Agilent Tech nologies, United States) to generate data, including retention time, signal intensity and m/z ratio for peak identification. Subsequently, SIMCAP 13.0 software (Umetric AB, CA, United States) was applied to do principal component analysis (PCA) to distinguish different scatters of the biological metabolites for taurine in HSCs, partial least squares discriminant analysis (PLSDA) to find statistically different meta bolites. Variable importance in the projection (VIP) plots (VIP > 1) of the PLSDA was used to find the exact potential biomarkers. Finally, the structure of the related metabolites and pathways was identified by comparing the m/z ratio and ion mode with the data obtained from free online databases including Human Metabolome Database (HMDB) (www.hmdb.ca), Metlin metabolomics database (http://metlin.scripps.edu/) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (www.genome.jp/kegg/pathway. html). MetPA network software [16] (http://metpa.
metabolomics.ca/Met PA/faces/Home.jsp) was used to do pathway analysis for taurine in HSCs.
RESULTS
Total ion current spectra of taurine in HSCs
In the current study, all the biological metabolites of taurine in HSCs were detected by HPLCESI/QTOFMS, which might provide useful information for unveiling the underlying molecular mechanisms of taurine in HSCs. The total ion current spectra of the samples 
PCA
PCA statistically divided all the detected metabolites into smaller clusters as principal components (PCs) to find the potential biomarkers. In this study, all the samples were classified into two small clusters between the control and taurinetreated cells in the PCA score plots (Figure 1 ), demonstrating that there were significant metabolic differences between the control and taurinetreated HSCs.
PLS-DA
Then, the potential important metabolites were further analyzed by using PLSDA. Consistent with the results of PCA, PLSDA plots showed two clear groups between the control and taurinetreated cells ( Figure  2 ). Moreover, a total of 27 metabolites in ESI + mode and five metabolites in ESI mode were found to be the significant metabolites between the control and taurinetreated cells (VIP > 1) (p < 0.05) ( Table 2) .
Structure identifications and pathway identification
The definite identity of the significant metabolites in the biological samples and their contributions to the biological processes are important for the current metabolomics study. Therefore, the structure of the related metabolites and pathways was identified by comparing the m/z ratio and ion mode with the data obtained from online free databases including HMDB (www.hmdb.ca), Metlin metabolomics database (http:// metlin.scripps.edu/) and KEGG pathway database (www.genome.jp/kegg/pathway.html). Additionally, 16 potential metabolic pathways were analyzed by MetPA network software and Deng X et al . Metabolomic profiling of taurine in HSCs three significant metabolic pathways (sphingolipid metabolism, glutathione metabolism and thiamine metabolism) were found to be the most important metabolic pathways for taurine in HSCs (Table 3 and Figure 3 ).
DISCUSSION
In this study, a simple chromatography method coupled with pathway analysis by using highperformance liquid chromatographytime electrospray ionization/ quadrupoletime of flight mass spectrometry (HPLC ESI/QTOFMS) was successfully performed for analyzing the mechanism of taurine in HSCs. A total of 32 significant differential endogenous metabolites were identified. Among the seven relevant pathways for taurine, sphingolipid metabolism pathway ( Figure  4 ), glutathione metabolism pathway ( Figure 5 ) and thiamine metabolism pathway were found to be the most important metabolic pathways for taurine in HSCs.
The sphingolipid metabolism pathway contributes greatly to structural functions and cellular signaling. For example, membrane sphingolipids can regulate cell proliferation, differentiation and death [1719] . Increasing evidence shows that sphingolipids are important in stress and ligandinduced hepatocellular death, which can cause several liver diseases like steatohepatitis, ischaemiareperfusion hepatic damage or hepatic cancer [20] . Additionally, increased levels of sphingolipids in specific cell subcompartments can cause liver dysfunctions and some inherited diseases. Tumour necrosis factor (TNF) is an important death receptor, and abnormal expression of TNF can cause many liver diseases [21] . Thus, TNF becomes an important target for liver disease. In this study, taurine was found to be able to regulate sphingolipid metabolism. Therefore, we hypothesize that taurine might be able to intervene the activation of HSCs and regulate TNF expression. HSCs from the control group HSCs from the taurine group
HSCs from the control group HSCs from the taurine group
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However, the exact mechanism of the action of taurine in the HSCs needs further investigation. Besides, lysophosphatidylcholine (LysoPC) can affect HSCs through several mechanisms. First, LysoPC can inhibit proliferation of endothelial cells and increase their apoptosis, thereby affecting the molecular structure of the endothelium and the proliferation of vascular smooth muscle cells [22, 23] . Second, LysoPC can downregulate endotheliumderived NO and activate the LOX1 receptor to desensitize eNOS, thus causing endothelial dysfunction [24] . Furthermore, activation of HSCs can lead to increased expression of genes relevant to lipid accumulation and increased levels of intracellular lipids. In this study, LysoPC was found as the significantly different metabolite between the control and taurinetreated groups. LysoPC is an important plasma lipid cell signaling molecule for LDL oxidization and can be generated by phospholipase A2 hydrolysis or phosphatidylcholine (PC) oxidation [25] . Thus, we hypothesize that the interventional effect of taurine on HSCs is related with lipid metabolism. This 
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HSCs from the control group HSCs from the taurine group HSCs from the control group HSCs from the taurine group was consistent with the finding of a previous study which showed that taurine can obviously decrease LDLC level [26] . Moreover, aminododecanoic acid, 2oxo4methyl thiobutanoic acid, oxododecenoic acid, valine, citric acid, thiamine, and Nacetylaspartate were also identified in the current study. It is therefore proposed that taurine may intervene HSCs through the valine, leucine and isoleucine biosynthesis pathway, cysteine and methionine metabolism pathway, citrate cycle (TCA cycle) pathway, alanine, aspartate and glutamate metabolism pathway, lysine degradation pathway, glyo Table 3 Results of MetPA pathway analysis 1 The total number of metabolites in each pathway; 2 The actually matched number according to the uploaded data; 3 The original p-value using enrichment analysis; 4 The adjusted p-value using false discovery rate. The table shows the detailed results from the pathway analysis. Since we tested many pathways at the same time, the p-values from enrichment analysis are further adjusted for multiple tests. In particular, the Hits is the actually matched number from the user uploaded data; the Raw p is the original p-value calculated from the enrichment analysis; the FDR p is the p-value adjusted using false discovery rate; the Impact is the pathway impact value calculated from pathway topology analysis. Sixteen potential metabolic pathways were analyzed by MetPA network software and three significant metabolic pathways (Sphingolipid metabolism, glutathione metabolism and thiamine metabolism) were found to be the most important metabolic pathways for taurine in HSCs; HSCs: Hepatic stellate cells.
Deng X et al . xylate and dicarboxylate metabolism pathway, arginine and proline metabolism pathway and aminoacyltRNA biosynthesis pathway. This study has several limitations. Validation of this current chromatography method using targeted meta bolomics and application of this current chromatography method on other cell lines or in vivo models need to be studied in the future. In addition, dosedependence of taurine should be clarified in the future.
To conclude, this study has found that there were distinct changes in the biological metabolites of taurine in HSCs by using HPLCESI/QTOFMS. A total of 32 significant differential endogenous metabolites and 3 differential metabolic pathways including sphingolipid pathway, glutathione pathway and thiamine metabolism pathway ( Figure 6 ) were identified, which might be of key importance in mediating the mechanism of action of taurine in HSCs.
COMMENTS
Background
It is well-known that quiescent hepatic stellate cells (HSC) may become matrixsecreting myofibroblasts upon activation and are the primary sources of extracellular matrix (ECM) during liver fibrogenesis. Thus, a novel therapeutic method for hepatic fibrosis can rely on the inhibition of activated HSCs. Taurine, a beta-amino acid with a simple structure that is extracted from animal tissue, has been investigated as a promising drug for the treatment of many hepatic injuries. In previous studies, taurine was found to significantly increase the apoptosis of HSCs and raise the concentrations of 19 proteins related to cellular apoptosis or oxidation in HSCs. However, the exact metabolic pathways and molecular mechanisms for taurine are still unknown.
Research frontiers
Metabolomics methods can be used to characterize the metabolic profiles of a biological system. Since metabolites with relatively low molecular weight are downstream products of biological processes, their identity and concentrations in a living biological system can provide biochemical signatures for globally tracking the physiological effects and exploring the drug effects. Therefore, metabolomics methods can be used to identify biomarkers for clinical drug therapy, especially in cancer research.
Innovations and breakthroughs
In this study, a simple chromatography method coupled with pathway analysis by using high-performance liquid chromatography-time electrospray ionization/ quadrupole-time of flight mass spectrometry was successfully performed for analyzing the mechanism of action of taurine in HSCs. A total of 32 significantly differential endogenous metabolites were identified, which may mediate the mechanism of action of taurine in HSCs. among the seven relevant pathways identified for taurine, sphingolipid metabolism pathway, glutathione metabolism pathway and thiamine metabolism pathway were found to be the most important metabolic pathways for taurine in HSCs.
Applications
Taurine, a beta-amino acid with a simple structure that is extracted from animal tissue, has been investigated as a promising drug for the treatment of many hepatic injuries. In previous studies, taurine was found to significantly increase the apoptosis of HSCs and raise the concentrations of 19 proteins related to cellular apoptosis or oxidation in HSCs. However, the exact metabolic pathways and molecular mechanisms for taurine are still unknown. Therefore, this study aimed at developing a reliable and simple method to identify important biological metabolites and relevant pathways for taurine in HSCs, in order to provide more data for taurine therapy.
Terminology
Hepatic fibrosis is a pathological condition characterized by excessive deposition of ECM proteins, which may led to the development of liver cirrhosis or even hepatocellular carcinoma in the absence of effective treatment.
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